Revenue and profit grew strongly in the first nine months of 2024, led by Pharma in Spain and international markets. Guidance for year-end is at the high end of forecasts, with continued investment in R&D and new plant operations.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.